Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV
Middle East respiratory coronavirus (MERS-CoV) is a newly emergent, highly pathogenic coronavirus that is associated with 34% mortality rate. MERS-CoV remains listed as priority pathogen by the WHO. Since its discovery in 2012 and despite the efforts to develop coronaviruses vaccines to fight agains...
Saved in:
| Main Authors: | Iman Almansour, B. Rabindran Jermy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2346390 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses
by: Siyuan Sun, et al.
Published: (2025-03-01) -
Lung-Selective Delivery of mRNA-Encoding Anti-MERS-CoV Nanobody Exhibits Neutralizing Activity Both In Vitro and In Vivo
by: Yuhang Zhang, et al.
Published: (2024-11-01) -
Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection
by: Wenxu Jia, et al.
Published: (2019-01-01) -
Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels
by: Wei Zhang, et al.
Published: (2019-01-01) -
An overview of SARS-COV-2: Virology, Epidemiology, Pathogenesis and Treatment
by: Ramesh Bhandari, et al.
Published: (2020-06-01)